National Beverage Corp. (0K50)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 34.56 |
|---|---|
| 52-week range | 29.00 – 38.73 |
| Return, 1 month / 3 months | +16.4% / +10.4% |
| Return, 1 year / 3 years | +7.2% / −10.2% |
| Trend | Uptrend |
| RSI (14) | 58 |
| Volatility (1 year) | 31.9% |
| Worst drawdown (1 year) | -19.5% |
| Average daily value traded | 0.00M USD |
| Dividend yield | 9.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
National Beverage Corp. is an American beverage company based in Fort Lauderdale, Florida. It makes and markets carbonated soft drinks and sparkling waters, including its LaCroix line of flavoured sparkling water and its Shasta and Faygo brands. The company also produces juices, energy drinks and other non-alcoholic beverages. Its customers are grocery stores, convenience retailers and other outlets across the United States, served largely through its own distribution operations.
National Beverage Corp. trades under the code 0K50 on the London Stock Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
National Beverage Corp. (0K50) trades on the London Stock Exchange in UK. It last closed at USD 34.56 on 27 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 1,813 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.2% and over the last three months it rose 10.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 9.4% | ||
| From 52-week high | -10.8% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 10.4% | ||
| 6-month return | 11.0% | ||
| 12-month return, skipping the last month | -7.9% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 31.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.5% | ||
| Liquidity | 8 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M USD | ||
| Zero-volume days | 10.0% | ||
| Income | 51 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 9.4% | ||
| Years with dividends | 3 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −1.2% |
|---|---|
| 1 month | +16.4% |
| 3 months | +10.4% |
| 6 months | +11.0% |
| 1 year | +7.2% |
| 3 years | −10.2% |
| 5 years | −21.7% |
Signals
| 50-day / 200-day average | 32.05 / 31.60 |
|---|---|
| Golden / death cross (60 days) | Golden, 34 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.12 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Jul 2026 | USD 3.2500 |
| 24 Jun 2024 | USD 3.2500 |
| 10 Dec 2021 | USD 3.0000 |
| 3 Dec 2020 | USD 6.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.